Clarithromycin

SCHEMBL13300525

CC[C@H]1OC(=O)[C@H](C)[C@@H](OC2C[C@@](C)(OC)[C@@H](O)[C@H](C)O2)[C@H](C)[C@@H](OC2O[C@H](C)C[C@H](N(C)C)[C@H]2O)[C@@](C)(OC)C[C@@H](C)C(=O)[C@H](C)[C@@H](O)[C@]1(C)O

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Full drug profile on Sugi Atlas →

Known targets — ChEMBL curated mechanism

rplA rplB rplC rplD rplE rplF rplJ rplK rplL rplM rplN rplO rplP rplQ rplR rplS rplT rplU rplV rplW rplX rplY rpmA rpmB rpmC rpmD rpmE rpmF rpmG rpmH rpmI rpmJ rpsA rpsB rpsC rpsD rpsE rpsF rpsG rpsH rpsI rpsJ rpsK rpsL rpsM rpsN rpsO rpsP rpsQ rpsR rpsS rpsT rpsU ykgM ykgO

The experimentally established mechanism targets of Clarithromycin. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.

Predicted protein targets (top 20)

	gene	UniProt	supporting neighbours	confidence
▸	CYP3A4	P08684	9/20	1.00

▸	KCNH2	Q12809	5/20	1.00

▸	ABCB1	P08183	2/20	1.00

▸	SLCO1B3	Q9NPD5	2/20	1.00

▸	SLCO1B1	Q9Y6L6	2/20	1.00

▸	AR	P10275	1/20	1.00

▸	MAPK1	P28482	1/20	1.00

▸	MLNR	O43193	2/20	0.92

▸	TSHR	P16473	2/20	0.92

▸	LMNA	P02545	2/20	0.92

▸	TDP1	Q9NUW8	1/20	0.92

▸	ALB	P02768	1/20	0.92

▸	CNR1	P21554	1/20	0.92

▸	HTR2A	P28223	1/20	0.92

▸	AOX1	Q06278	1/20	0.92

▸	CYP1B1	Q16678	1/20	0.92

▸	ABCC4	O15439	1/20	0.77

▸	ABCB11	O95342	1/20	0.77

▸	PGR	P06401	1/20	0.77

▸	HTR1A	P08908	1/20	0.77

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compound	similarity	top predicted	shared targets
Clarithromycin SCHEMBL13575758	1.00	CYP3A4 (1.00)	CYP3A4KCNH2ABCB1SLCO1B3SLCO1B1
Clarithromycin SCHEMBL13374687	1.00	CYP3A4 (1.00)	CYP3A4KCNH2ABCB1SLCO1B3SLCO1B1
Clarithromycin SCHEMBL19585126	1.00	CYP3A4 (1.00)	CYP3A4KCNH2ABCB1SLCO1B3SLCO1B1
Clarithromycin SCHEMBL24064961	1.00	CYP3A4 (1.00)	CYP3A4KCNH2ABCB1SLCO1B3SLCO1B1
Clarithromycin SCHEMBL15474392	1.00	CYP3A4 (1.00)	CYP3A4KCNH2ABCB1SLCO1B3SLCO1B1
Clarithromycin SCHEMBL23309064	1.00	CYP3A4 (1.00)	CYP3A4KCNH2ABCB1SLCO1B3SLCO1B1
Clarithromycin SCHEMBL14342512	1.00	CYP3A4 (1.00)	CYP3A4KCNH2ABCB1SLCO1B3SLCO1B1
Clarithromycin SCHEMBL23854898	1.00	CYP3A4 (1.00)	CYP3A4KCNH2ABCB1SLCO1B3SLCO1B1
Clarithromycin SCHEMBL38124	1.00	CYP3A4 (1.00)	CYP3A4KCNH2ABCB1SLCO1B3SLCO1B1
Clarithromycin SCHEMBL14495684	1.00	CYP3A4 (1.00)	CYP3A4KCNH2ABCB1SLCO1B3SLCO1B1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

Patent	Title	Assignee	Published	Priority	Filing	Country	Status
US-20200040024-A1	CONVERGENT PROCESSES FOR PREPARING MACROLIDE ANTIBACTERIAL AGENTS	Têtard, Inc. (US)	2020-02-06	—	—	US	disclosed
US-20190023731-A1	CONVERGENT PROCESSES FOR PREPARING MACROLIDE ANTIBACTERIAL AGENTS	TETARD, INC.	2019-01-24	—	—	US	disclosed
US-9751908-B2	Convergent processes for preparing macrolide antibacterial agents	CEMPRA PHARMACEUTICALS, INC. (US)	2017-09-05	—	—	US	disclosed
US-9751908-B2	Convergent processes for preparing macrolide antibacterial agents	CEMPRA PHARMACEUTICALS, INC. (US)	2017-09-05	—	—	US	disclosed
US-20160046660-A1	CONVERGENT PROCESSES FOR PREPARING MACROLIDE ANTIBACTERIAL AGENTS	TETARD, INC.	2016-02-18	—	—	US	disclosed
US-20160046660-A1	CONVERGENT PROCESSES FOR PREPARING MACROLIDE ANTIBACTERIAL AGENTS	TETARD, INC.	2016-02-18	—	—	US	disclosed
US-8076301-B2	10-substituted macrolide antibiotics	C10 PHARMA AS (NO)	2011-12-13	—	—	US	disclosed
US-20100137234-A1	10-SUBSTITUTED MACROLIDE ANTIBIOTICS	C10 PHARMA AS (NO)	2010-06-03	—	—	US	disclosed
US-7332476-B2	Pyridyl substituted ketolide antibiotics	NOVARTIS AG (CH)	2008-02-19	—	—	US	disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

Patent	Title	Text reads most about	Predicted target · text-rank
US-20160046660-A1	CONVERGENT PROCESSES FOR PREPARING MACROLIDE ANTIBACTERIAL AGENTS	COASY, TKT, CYP51A1	CYP3A4 403/4885KCNH2 1134/4885ABCB1 2369/4885
US-20190023731-A1	CONVERGENT PROCESSES FOR PREPARING MACROLIDE ANTIBACTERIAL AGENTS	COASY, TKT, CYP51A1	CYP3A4 403/4885KCNH2 1134/4885ABCB1 2369/4885
US-20200040024-A1	CONVERGENT PROCESSES FOR PREPARING MACROLIDE ANTIBACTERIAL AGENTS	COASY, TKT, CYP51A1	CYP3A4 403/4885KCNH2 1134/4885ABCB1 2369/4885
US-20100137234-A1	10-SUBSTITUTED MACROLIDE ANTIBIOTICS	RPLP0, RPS10, MRPL21	CYP3A4 608/4885KCNH2 3308/4885ABCB1 263/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.